Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-26
2006-12-26
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
07153829
ABSTRACT:
Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4118481 (1978-10-01), Shnabel
patent: 4153687 (1979-05-01), Shnabel
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4609725 (1986-09-01), Brady et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5576294 (1996-11-01), Norris et al.
patent: 5677146 (1997-10-01), Sprecher et al.
patent: 5719041 (1998-02-01), Lazarus et al.
patent: 5786328 (1998-07-01), Dennis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5843895 (1998-12-01), Lazarus et al.
patent: 5994125 (1999-11-01), Markland et al.
patent: 6010880 (2000-05-01), Markland et al.
patent: 6057287 (2000-05-01), Markland et al.
patent: 6071723 (2000-06-01), Markland et al.
patent: 6103499 (2000-08-01), Markland et al.
patent: 6333402 (2001-12-01), Markland et al.
patent: 6423498 (2002-07-01), Markland et al.
patent: 2004/0038893 (2004-02-01), Ladner et al.
patent: 2004/0053206 (2004-03-01), Cicardi et al.
patent: AT E 275 583 (2005-04-01), None
patent: 2 180 950 (2005-03-01), None
patent: 695 33 472 (2006-01-01), None
patent: 0 285 123 (1988-10-01), None
patent: 0 621 871 (1991-07-01), None
patent: 0 621 870 (1997-05-01), None
patent: 0 739 355 (2004-08-01), None
patent: 1 484 339 (2004-08-01), None
patent: WO 89/10374 (1989-11-01), None
patent: WO 93/14120 (1993-07-01), None
patent: WO 93/14121 (1993-07-01), None
patent: WO 93/14122 (1993-07-01), None
patent: WO 95/18830 (1995-07-01), None
patent: WO 95/21601 (1995-08-01), None
patent: WO 03/103475 (2003-12-01), None
patent: WO 2004/019968 (2004-11-01), None
Adelman, et al., Proteolysis of Platelet Glycoprotein Ib by Plasmin Is Facilitated by Plasmin Lysine-Binding Regions,Blood, vol. 68 (6): 1280-1284, (Dec. 1986).
Albrecht, et al., Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter-α-Trypsin Inhibitors From several Mammalian Sera,Hoppe-Seyler's Z . Physiol. Chem., vol. 364: 1697-1702, (Dec. 1983).
Albrecht, et al.., Elastase Inhibition by the Inter-α-Trypsin Inhibitor and Derived Inhibitors of Man and Cattle,Hoppe-Seyler's Z. Physiol. Chem., vol. 364: 1703-1708, (Dec. 1983).
Anba, et al., Improving the Stability of a Foreign Protein in the Periplasmic Space ofEscherichia coli, Biochimie, vol. 70(6): 727-33, (1988).
Angliker, et al., The Synthesis of Lysylflouromethanes and their Properties as Inhibitors of Trypsin, Plasmin and Cathepsin B,Biochemistry, vol. 241 (3): 871-875, (Jan. 1987).
Atherton, et al., Peptide Synthesis. Part 21Procedures for Solid Phase Synthesis using Nα-Fluorenylmethycarbonlamino-acids on Polyamide Supports. Synthesis of Substance P and of Acyl Carrier Protein 65-74 Decapeptide,J Chem Soc Perkins Trans, vol. 1: 538-546, (1981).
Auerswald et al., Expression, Isolation and Characterization of Recombinant [Arg15, Glu52] Aprotinin,Biol Chem Hoppe-Seyler, vol. 369 (supplement): 27-35, (May, 1988).
Baba, M., et al., States of Tyrosyl Residues and Circular Dichroism of Kunitz Trypsin Inhibitor,J. Biochem. (Tokyo), vol. 65 (1): 113-121, (1969).
Balduyck, et al., Human Urinary Proteinase Inhibitor: Inhibitory Properties and Interaction with Bovine Trypsin,Biol Chem Hoppe-Seyler, vol. 366; 9-14, (Jan., 1985).
Baneyx and Georgiou, In Vivo Degradation of Secreted Fusion Proteins by theEscherichia coliOuter Membrane Protease OmpT,J. Bacterial., vol. 172 (1): 491-494, (Jan. 1990).
Baneyx and Georgiou, Construction and Characterization ofEscherichia coliStrains Deficient in Multiple Secreted Proteases: Protease III Degrades High-Molecular-Weight Substrates In Vivo,J Bacteriol., vol. 173 (8): 2696-2703, (Apr. 1991).
Berndt, et al., Designed Replacement of an Internal Hydration Water Molecule in BPTI: Structural and Functional Implications of a Glycine-to-Serine Mutation,Biochemistry, vol. 32: 4564-4570, (1993).
Bhoola et al., Bioregulation of Kinins: Kallikreins, Kininogens and Kininases,Pharmacological Reviews, vol. 44 (1): 1-80, (1992).
Browne, et al., Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells, Genebank, Entry M74220.
Broze, et al., Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor,Biochemistry, vol. 29 (33): 7539-7546, (Aug. 21, 1990).
Brus et al., Disease Severity Is Correlated with Plasma Clotting and Fibrinolytic and Kinin-Kallikrein Activity in Neonatal Respiratory Distress Syndrome,Pediatric Research,vol. 41 (1): 120-127, (1997).
Budavari, ed., Merck index, eleventh ed., ISBN 911910-28-X, entries 923, 1745, 2740, 7425, (1989).
Carey, et al.,Advanced Organic Chemistry,3rd Edition, Part B: Reactions and Synthesis, Plenum Press, New York: 678-686, (1990).
Chen, et al., Solution Structure of a Kunitz-type Chymotrypsin Inhibitor Isolated form the Elapid SnakeBungarus Fasciatus, Journal of Biological Chemistry,vol. 276: 45079-45087, (2001).
Chung, et al., GenBank, Accession #P03952, (1995).
Colman, et al.,Hemostasis and Thrombosis,Chapter 1,2ndEdition, Basic Priniciples and Clinical Practice: 3-17, (1987).
Colman, R.W., et al., “Activation of the Kallikrein-Kinin System in Arthritis and Enterocolitis in Genetically Susceptible Rats: Modulation by a Selective Plasma Kallikrein Inhibitor,”Proc. Assoc. Am. Physicians,vol. 109 (1):10-22, (1997).
Cumming and Nimmo, Hemodynamic, Renal, and Hormonal Aprotinin in an Ovine Model of Septic Shock,Critical Care Medicine,vol. 20 (8): 1134-1139, (1992).
Currie et al., Design and Synthesis of a Bicyclic Non-Peptide β-Bend Mimetic of Enkephalin,Tetrahedron,vol. 49 (17): 3489-3500, (1993).
DeLa Cadena, et al., Role of Kallikrein-Kinin System in the Pathogenesis of Bacterial Cell Wall-Induced Inflammation and Enterocolitis,Transact. Assoc. Am. Physicians,105: 229-237, (1992).
DeLa Cadena, et al., Inhibition of Plasma Kallikrein Prevents Peptidoglycan-Induced Arthritis in the Lewis Rat,FASEB Journal,vol. 9: 446-452, (1995).
Dennis & Lazarus, Kunitz Domain Inhibitors of Tissue Factor—Factor VIIa (I),Journal of Biological Chemistry,vol. 269 (35): 22129-22136, (1994).
Dennis & Lazarus, Kunitz Domain Inhibitors of Tissue Factor—Factor VIIa (II),Journal of Biological Chemistry,vol. 269 (35): 22137-22144, (1994).
Dennis & Lazarus, Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display,Journal of Biological Chemistry,vol. 270 (43): 25411-25417, (1995).
Diaz et al., The Design of Water Soluble β-Sheet Structure Based On a Nucleation Strategy,Tetrahedron,vol. 49 (17): 3533-3545, (1993).
Dimaio et al., A New Class of Potent Thrombin Inhibitors That Incorporates a Scissile Pseudopeptide Bond,Federation of European Biochemical Societies,vol. 282 (1): 47-52, (Apr. 1991).
Eigenbrot et al., Structural Effects Induced by Removal of a Disulfide-bridge: the X-ray Structure of C30A/C15A Mutant of Basic Pancreatic Trypsin Inhibitor at 1.6 A,Protein Engineering,vol. 3 (7): 591-598, (1990).
Ellis et al., The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion,Ann NY. Acad. Sci.,vol. 667: 13-31, (1992).
Fildler & Ellis, The Implications of Angiogenesis for the Biology and Chemistry of Cancer Metastasis,Cell,vol. 79: 185-188, (Oct. 21, 1994).
Fields & Noble, Solid Phase Peptide Synthesis Utilizing 9-fluorenylmethocarbonyl Amino Acids,Int. J. Peptide Protein Research,vol. 35: 161-214, (1990).
Fraedrich, et al., Reduction of Blood Transfusion requirement in Open Heart Surgery By Administration of High Doses of Aprotinin-Preliminary Results,Thorac Cardiovasc Surgeon,vol. 37 (2): 89-91, (1989).
Freidinger, et al., Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides,Journal of Organic Chemistry,vol. 47: 104-109, (1982).
Gar
Bergamaschini Luigi
De Simoni Maria Grazia
Hirani Shirish
Ladner Robert C.
Ley Arthur C.
Carlson Karen Cochrane
Dyax Corp.
Tsay Marsha
LandOfFree
Kallikrein-inhibitor therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kallikrein-inhibitor therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kallikrein-inhibitor therapies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3712981